Kenya and Pfizer review MoU on vaccines, local manufacturing and regional hub role
Key points
- Ministry of Health and Pfizer Overseas LLC reviewed implementation of their Memorandum of Understanding.
- Witnessed by Medical Services PS Dr Ouma Oluga and Pfizer Access/Accord VP Ali Besri.
- MoU covers not-for-profit access to medicines and vaccines, supply-chain strengthening, regulatory collaboration and health workforce development.
- Kenya wants the partnership expanded to clinical trials, technology transfer, local manufacturing and East Africa logistics hub status; Joint Coordination Committee to be operationalised.
Vaccine diplomacy only matters when cold-chain trucks leave the warehouse. Kenya has reviewed progress under its Ministry of Health–Pfizer Overseas LLC memorandum, KBC reported, with Medical Services Principal Secretary Dr Ouma Oluga and Pfizer Biopharmaceuticals Group Vice President for Access and Accord in Emerging Markets Ali Besri present.
The MoU supports not-for-profit access to Pfizer medicines and vaccines, supply-chain strengthening, regulatory collaboration and health workforce development. Oluga pressed for a broader strategic partnership: clinical trials and research, technology transfer, local manufacturing, and positioning Kenya as a logistics and distribution hub for East Africa. Officials stressed operationalising the Joint Coordination Committee under the agreement to oversee delivery among the ministry, Pfizer, the Pharmacy and Poisons Board, Kenya Medical Supplies Authority and other agencies. The package is tied to Kenya’s Health Products and Technologies Local Manufacturing Strategy 2026–2030. The agreement took effect in April 2025 and was renewed in May 2026.
MoUs do not stock shelves
Access language is easy; technology transfer and local fill-finish capacity are hard. Without published milestones and public tendering where required, the hub vision risks remaining a photo opportunity.
Health desk: Health. Verified principals, MoU themes and dates from KBC.
Parliament’s health committee should demand a public implementation dashboard. County depots need training schedules before new products arrive.
Patients will measure success in stock-outs avoided, not in MoU renewal press notes.
Official gazettes, court rulings and agency circulars may update these facts after publication; readers should verify any deadline, fee or court date against primary sources before acting.
The Joint Coordination Committee should publish quarterly scorecards on trials, tech transfer and stock availability so the 2026–2030 manufacturing strategy is measurable outside boardrooms.
Based on KBC reporting of the MoH–Pfizer review. Commercial terms remain subject to the parties’ agreements.
